In line with the finding that TNFα production and secretion is upregulated in AT from human patients with obesity (130), these studies highlight the therapeutic potential of targeting TNFα to combat dyslipidemia and insulin resistance in CMS. This evidence concerns the gene TNF and Insulin resistance.